[{"id":"69a88472-75f1-4a2a-90e1-8b0bf04a99cd","acronym":"AALL1521","url":"https://clinicaltrials.gov/study/NCT02723994","created_at":"2021-01-18T13:19:54.627Z","updated_at":"2024-07-02T16:35:23.552Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02723994 - AALL1521","lead_sponsor":"Incyte Corporation","biomarkers":" JAK2 • CRLF2 • JAK1 • IL7R • EPOR • SH2B3","pipe":" | ","alterations":" CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 fusion • SH2B3 deletion","tags":["JAK2 • CRLF2 • JAK1 • IL7R • EPOR • SH2B3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 fusion • SH2B3 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Erwinase (erwinia asparaginase)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 09/30/2016","start_date":" 09/30/2016","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-01-12"},{"id":"434adfdd-8113-4766-9f0b-9b5c20203527","acronym":"","url":"https://clinicaltrials.gov/study/NCT03571321","created_at":"2021-01-18T17:34:27.181Z","updated_at":"2024-07-02T16:35:27.762Z","phase":"Phase 1","brief_title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03571321","lead_sponsor":"University of Chicago","biomarkers":" JAK2 • CRLF2 • IL7R • SH2B3","pipe":" | ","alterations":" CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 rearrangement • SH2B3 deletion","tags":["JAK2 • CRLF2 • IL7R • SH2B3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 rearrangement • SH2B3 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/28/2019","start_date":" 05/28/2019","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/05/2027","study_completion_date":" 09/05/2027","last_update_posted":"2023-11-29"},{"id":"ea03117e-1915-40c6-8ad5-83f311e92718","acronym":"HEM-iSMART C","url":"https://clinicaltrials.gov/study/NCT05745714","created_at":"2023-02-27T15:01:08.545Z","updated_at":"2024-07-02T16:35:54.631Z","phase":"Phase 1/2","brief_title":"HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","source_id_and_acronym":"NCT05745714 - HEM-iSMART C","lead_sponsor":"Princess Maxima Center for Pediatric Oncology","biomarkers":" JAK2 • CRLF2 • JAK1 • IL7R • STAT5B • P2RY8 • EPOR • PTPN2 • SH2B3 • DDX3X • USP9X","pipe":" | ","alterations":" CRLF2 rearrangement • CRLF2 overexpression • IL7R mutation • IGH-CRLF2 fusion • PTPN2 mutation","tags":["JAK2 • CRLF2 • JAK1 • IL7R • STAT5B • P2RY8 • EPOR • PTPN2 • SH2B3 • DDX3X • USP9X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CRLF2 rearrangement • CRLF2 overexpression • IL7R mutation • IGH-CRLF2 fusion • PTPN2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • Jakafi (ruxolitinib) • cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 10/01/2030","primary_completion_date":" 10/01/2030","study_txt":" Completion: 10/01/2030","study_completion_date":" 10/01/2030","last_update_posted":"2023-02-27"}]